Next 10 |
home / stock / cybn / cybn articles
Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024. See prev...
The TDR Three Key Takeaways: Positive Clinical Progress: Cybin Inc. has reported significant advancements in its clinical programs, notably achiev...
Psychedelics biotech Cybin Inc. (NYSE:CYBN) has received clearance from the Food and Drug Administration (FDA) on its Investigational New Drug (IND...
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD A decade after it was founded as a wholly-owned ...
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substance...
Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) announced positive safety and efficacy data from its Phase 1 studies of CYB004 (intravenou...
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit...
Defense Dept. Funds Ketamine Study For PTSD Treatment A DOD Health Agency-funded adaptive platform trial for alternative treatments for ...
Next-generation psychedelics biotech Cybin Inc. (NYSE: CYBN) released the full Phase 2 trial results of its deuterated psilocybin derivative CYB003...
News, Short Squeeze, Breakout and More Instantly...
Cybin Inc. Company Name:
CYBN Stock Symbol:
NYSE Market:
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, is announcing its participation at the 27th Annual Milken Institute Global Conference, set to take place May 5-8, 2024, at th...
- Doug Drysdale, CEO, to appear on panel entitled “Collaborating for Improved Mental Health,” on May 8, 2024 - Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company ...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, is reporting that its research has been published in a prestigious biweekl...